The Covid Era Tech Promises To Reinvent Cancer Treatment
The Covid Era Tech Promises To Reinvent Cancer Treatment
新冠時代技術承諾重塑癌症治療
Pfizer Inc (NYSE:PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ:MRNA) in turning to oncology for its next growth story. Both Moderna and Pfizer made history during the COVID-19 pandemic thanks to mRNA technology. Now, Moderna and Pfizer embarked on a journey to treat cancer with mRNA science. By using mRNA-based next-generation CRC screening tests, a much smaller and less known pharma player, Mainz Biomed N.V. (NASDAQ:MYNZ), is already redefining standards in early cancer detection with its flagship colorectal cancer test ColoAlert, while also tackling cancer prevention.
輝瑞公司（紐交所：PFE）承諾在治療癌症方面取得更大突破，與其COVID疫苗同行者現代美國公司（納斯達克：MRNA）一起，轉向腫瘤學尋找下一個增長故事。在COVID-19大流行期間，現代美國公司和輝瑞公司均因mRNA技術而創造了歷史。現在，現代美國公司和輝瑞公司開始了利用mRNA科學治療癌症的旅程。通過使用基於mRNA的下一代CRC篩查測試，一個規模較小且不太知名的製藥公司——邁恩斯生物醫藥股份有限公司（納斯達克：MYNZ），已經在早期癌症檢測領域重新定義了標準，其旗艦結直腸癌檢測產品ColoAlert，同時也在開展癌症預防工作。
Moderna...
現...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。